Literature DB >> 30238207

Cerebral white matter Hyperintensities in HIV-positive patients.

Alice Trentalange1, Adolfo Prochet2, Daniele Imperiale3, Jessica Cusato4, Mariacristina Tettoni4, Giuseppe Nunnari5, Ambra Barco4, Stefano Bonora4, Giovanni Di Perri4, Andrea Calcagno4.   

Abstract

White matter hyperintensities (WMHs) have been associated with neurological complications including cognitive impairment. WMHs have been often described in HIV positive subjects and they have been linked to neurocognitive impairment, cerebrospinal fluid (CSF) residual viral replication and biomarkers of monocyte activation. Aim of this study was to grade WMHs in HIV-positive individuals using a simple visual scale and to explore their severity with clinical, neurocognitive and biomarker characteristics. Brain MRIs were retrospectively evaluated by two reviewers who rated WMHs following the "age-related white matter changes (ARWMC)" scale. 107 adult HIV-positive patients receiving lumbar punctures for clinical reasons were included. 70 patients (66.6%) were diagnosed with WMHs. Average WMH scores were higher in treated [7 (1-11)] vs. naïve individuals [3 (0-6)] (p = 0.008). Higher WHMs scores were observed in patients with chronic renal impairment along with chronic hepatitis (naïve) and longer HIV duration (treated participants). No consistent associations between plasma, CSF biomarkers and WMHs scores were found. 45 patients underwent full neurocognitive tests and WMHs scores were non-significantly higher in patients diagnosed with HAND [6.5 (0.5-8.3) vs. 1.5 (0-7), p = 0.165]; screening (IHDS and FAB), visuo-spatial (Corsi's) and auditory-verbal memory (disillabic words repetition) tests scored worse in patients with higher WMHs. In our population of HIV-positive patients with low CD4 nadir and partial CD4 cell recovery the burden of WMHs was associated with the duration of HIV infection and with commonly observed comorbidities (such as renal and hepatic impairment). Given the association with worse neurocognition, further studies on tailored interventions are needed.

Entities:  

Keywords:  Brain magnetic resonance imaging; HIV; Neopterin; Neurocognition; Visual scale

Year:  2020        PMID: 30238207     DOI: 10.1007/s11682-018-9966-1

Source DB:  PubMed          Journal:  Brain Imaging Behav        ISSN: 1931-7557            Impact factor:   3.978


  5 in total

1.  Cerebrovascular Contributions to Neurocognitive Disorders in People Living With HIV.

Authors:  Jose Gutierrez; Tiffany N Porras; Moka Yoo-Jeong; Farid Khasiyev; Kay C Igwe; Krystal K Laing; Adam M Brickman; Marykay Pavol; Rebecca Schnall
Journal:  J Acquir Immune Defic Syndr       Date:  2021-09-01       Impact factor: 3.771

2.  Longitudinal Effects of Combination Antiretroviral Therapy on Cognition and Neuroimaging Biomarkers in Treatment-Naive People With HIV.

Authors:  Miriam T Weber; Alan Finkelstein; Md Nasir Uddin; Elizabeth Asiago Reddy; Roberto C Arduino; Lu Wang; Madalina E Tivarus; Jianhui Zhong; Xing Qiu; Giovanni Schifitto
Journal:  Neurology       Date:  2022-06-22       Impact factor: 11.800

3.  Association of White Matter Hyperintensities With HIV Status and Vascular Risk Factors.

Authors:  Yair Mina; Tianxia Wu; Hsing-Chuan Hsieh; Dima A Hammoud; Swati Shah; Chuen-Yen Lau; Lillian Ham; Joseph Snow; Elizabeth Horne; Anuradha Ganesan; Stanley I Rapoport; Edmund C Tramont; Daniel S Reich; Brian K Agan; Avindra Nath; Bryan R Smith
Journal:  Neurology       Date:  2021-02-26       Impact factor: 9.910

4.  HIV-Associated Neurocognitive Impairment in the Modern ART Era: Are We Close to Discovering Reliable Biomarkers in the Setting of Virological Suppression?

Authors:  Alessandra Bandera; Lucia Taramasso; Giorgio Bozzi; Antonio Muscatello; Jake A Robinson; Tricia H Burdo; Andrea Gori
Journal:  Front Aging Neurosci       Date:  2019-08-02       Impact factor: 5.750

5.  Human immunodeficiency virus-related decreases in corpus callosal integrity and corresponding increases in functional connectivity.

Authors:  Shana A Hall; Ryan P Bell; Simon W Davis; Sheri L Towe; Taylor P Ikner; Christina S Meade
Journal:  Hum Brain Mapp       Date:  2021-08-12       Impact factor: 5.038

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.